Simply Wall St
Recent trading in Strive (ASST) has drawn attention after a sharp move over the past 3 months, putting fresh focus on how its asset management model and financial profile stack up today.
For context, Strive’s recent surge has come on top of a 23.5% 30 day share price return and a 129.1% 90 day share price return. However, the 1 year total shareholder return is still down 42.3%, with the 3 year total shareholder return down 7.6%. This suggests that recent momentum is strong but rebuilding from a weaker longer term base.
Scan how Strive’s surge compares with other high quality opportunities by reviewing the hand picked 19 high quality undiscovered gems now on Simply Wall St.
Strive has already delivered a very sharp rebound, yet the share price still sits below both its 1 year and 3 year total return marks. Is most of the easy upside gone? Or is the rerating only getting started?
Preferred Price-to-Book of 4x for Strive: Is it justified?
Valuation for Strive currently leans heavily on its price-to-book profile, with the stock trading at a P/B of 4x. This implies investors are paying four times the company’s book value at the last close of $30.03.
The P/B ratio compares the share price with the accounting value of net assets. It can be a useful yardstick for asset managers and financial groups where earnings are still volatile or loss making. For Strive, which remains unprofitable today, this metric helps frame what the market is willing to pay for its current balance sheet and underlying asset management platform rather than for established profitability.
Against that backdrop, Strive is described as expensive compared to the broader US Medical Equipment industry average P/B of 2.6x. However, the same 4x multiple is highlighted as good value against a peer group that averages 8x. The stock is therefore priced well above the wider sector, but materially below closer comparators. This signals that investors are already paying a premium for Strive relative to the industry while still applying a discount relative to peers with similar characteristics.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 4x (ABOUT RIGHT)
Still, the story around Strive can change quickly if its unprofitable status persists or if revenue growth from its US$8.5m base disappoints.
Find out about the key risks to this Strive narrative.
Next Steps
Strive clearly splits opinion, with sharp recent gains on one side and earlier declines on the other. Check the full picture quickly and ground your own judgment using the 1 key reward and 3 important warning signs.
